Use of evidence-based pharmacotherapy after myocardial infarction in Estonia

Marandi, Toomas; Baburin, Aleksei; Ainla, Tiia
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p358
Academic Journal
Background: Mortality from cardiovascular disease in Estonia is among the highest in Europe. The reasons for this have not been clearly explained. Also, there are no studies available examining outpatient drug utilization patterns in patients who suffered from acute myocardial infarction (AMI) in Estonia. The objective of the present study was to examine drug utilization in different age and gender groups following AMI in Estonia. Methods: Patients admitted to hospital with AMI (ICD code I21-I22) during the period of 01.01.2004-31.12.2005 and who survived more than 30 days were followed 365 days from the index episode. Data about reimbursed prescriptions of beta-blockers (BBs), angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACE/ARBs) and statins for these patients was obtained from the database of the Estonian Health Insurance Fund. Data were mainly analysed using frequency tables and, where appropriate, the Pearson's ?2 test, the Mann-Whitney U-test and the t-test were used. A logistic regression method was used to investigate the relationship between drug allocation and age and gender. We presented drug utilization data as defined daily dosages (DDD) per life day in four age groups and described proportions of different combinations used in men and women. Results: Four thousand nine hundred patients were hospitalized due to AMI and 3854 of them (78.7%) were treated by BBs, ACE/ARBs and/or statins. Of the 4025 inpatients who survived more than 30 days, 3799 (94.4%) were treated at least by the one of drug groups studied. Median daily dosages differed significantly between men and women in the age group 60-79 years for BBs and ACE/ARBs, respectively. Various combinations of the drugs studied were not allocated in equal proportions for men and women, although the same combinations were the most frequently used for both genders. The logistic regression analysis adjusted to gender and age revealed that some combinations of drugs were not allocated similarly in different age and gender groups. Conclusions: Most of the patients were prescribed at least one of commonly recommended drugs. Only 40% of them were treated by combinations of beta-blockers, ACE inhibitors/angiotensin II receptor blockers and statins, which is inconsistent with guideline recommendations in Estonia. Standards of training and quality programs in Estonia should be reviewed and updated aiming to improve an adherence to guidelines of management of acute myocardial infarction in all age and gender groups.


Related Articles

  • Many CAD patients referred for invasive intervention are on suboptimal medical therapy.  // Modern Medicine;May96, Vol. 64 Issue 5, p30 

    Reports on the suboptimal chemotherapy of patients with coronary artery disease (CAD). Safety of using suboptimal medical therapy instead of invasive interventions.

  • Increased drug therapy may be all that CAD patients need.  // Geriatrics;May96, Vol. 51 Issue 5, p56 

    Reports on treatment of people with coronary artery disease. Effectiveness of increased medications.

  • Fix for furry arteries. Coghlan, Andy // New Scientist;11/15/97, Vol. 156 Issue 2108, p6 

    Highlights research on drugs for tackling the root cause of blockages in coronary arteries. Suppression of levels of cholesterol; Disruption of endothelial inflammation; Prevention of activation of genes in endothelial cells that amplify inflammation.

  • Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Riviere, Marc; Wang, Shanshan // CMAJ: Canadian Medical Association Journal;04/01/97, Vol. 156 Issue 7, p991 

    Determines the cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease (CAD) in Canada. Outcome measures of the study; Reduced mortality and morbidity among patients given simvastatin compared to control subjects; Suggestion that simvastatin provides a...

  • Combo therapy for 2° CHD prevention not uniform in the US.  // PharmacoEconomics & Outcomes News;2/20/2010, Issue 597, p6 

    The article discusses research by J. Tija et al published in the January 2010 issue of the journal of "Drugs and Aging" on the effectivity of combination drug therapy for the secondary prevention of coronary heart disease (CHD) in the U.S. and the subpopulation in danger of underusing the therapy.

  • Lipid-lowering therapy after coronary artery bypass grafting: Time for more aggressive intervention. Lucas Jr., B. Daniel // American Journal of Health-System Pharmacy;11/1/2002, Vol. 59 Issue 21, p2101 

    Reflects the approach of health care providers toward lipid management in the patient with coronary heart disease (CHD). Comparison between primary and secondary prevention of CHD; Evaluation of the lipid-lowering therapy ; Attempts to enhance medical compliance and reduce cholesterol levels.

  • AFFAIRS OF THE HEART. Karpa, Kelly Dowhower // Drug Topics;10/20/2003, Vol. 147 Issue 20, pHSE11 

    Proposes the use of cocktail drugs to treat acute coronary syndrome. Role of pharmacists; Function of beta-blockers; Function of antiplatelet/anticoagulation drugs; Lipid-lowering medications.

  • A CASE REPORT OF 5-FLUOROURACIL-INDUCED CORONARY ARTERY VASOSPASM. Connolly, Suzanne; Scott, Peter; Cochrane, L. David; Harte, Robert // Ulster Medical Journal;2010, Vol. 79 Issue 3, p135 

    A letter to the editor is presented that describes the case of a 76-year-old man diagnosed with coronary artery vasopasm induced by the chemotherapeutic agent 5-Flurouracil.

  • Pravastatin/cholestyramine combination is more cost-effective than monotherapy.  // Modern Medicine;Jan98, Vol. 66 Issue 1, p21 

    Discusses the abstract of the article `Pravastatin alone and in combination with low cholestyramine in patients with primary hypercholesterolemia and coronary artery disease,' by M.K. Ito and R. Shabetai, which appeared in the September 15, 1997 issue of `American Journal of Cardiology.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics